In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day.
Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices. Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients.
The stock market has already marked its fair share of high highs and low lows in 2023, and we're not even a full month in. Vertex Pharmaceuticals (NASDAQ: VRTX) isn't one of those healthcare stocks with a massive portfolio of drugs that has tapped out its heyday of superior growth. At present, Vertex has just four approved drugs in its portfolio, and all of them treat the genetic disease cystic fibrosis.